Most cited papers from Dr Falk Pharma (Germany)

Dr Falk Pharma (Germany)

What are the most cited papers from Dr Falk Pharma (Germany)?

The most cited paper from Dr Falk Pharma (Germany) is "Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis" (Michael Peter Manns, Marek Woynarowski, Wolfgang Kreisel et al., 2010), with 447 citations. Next come "Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial" (306) and "norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis" (295).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 34 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis Michael Peter Manns, Marek Woynarowski, Wolfgang Kreisel et al. · Gastroenterology Open access	23 Jun 2010	447
2	Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial Alfredo José Lucendo et al. · Gastroenterology Open access	26 Mar 2019	306
3	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis Peter Fickert, Gideon Morris Hirschfield, Gerald Denk et al. · Journal of Hepatology Open access	18 May 2017	295
4	A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease Detlef Schuppan et al. · New England Journal of Medicine Open access	30 Jun 2021	237
5	Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis Alex Straumann et al. · Gastroenterology Open access	25 Jul 2020	220
6	Budesonide versus prednisone in the treatment of active Crohn's disease Simon Bar–Meir, Yehuda Chowers, Alexandra Lavy et al. · Gastroenterology Open access	Oct 1998	217
7	A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis Stephan Miehlke et al. · Gut Open access	19 Mar 2015	214
8	The Prevalence of COPD Paul Stang, EVA G. LYDICK, Cheryl Silberman et al. · CHEST Journal	May 2000	206
9	Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial Wolfgang Kruis, Gediminas Kiudelis, István András Rácz et al. · Gut Open access	2 Oct 2008	204
10	Development of encorafenib for BRAF-mutated advanced melanoma Peter Koelblinger, Thuerigen Olaf, Reinhard Dummer · Current Opinion in Oncology Open access	30 Nov 2017	180
11	Budesonide Is Effective in Treating Lymphocytic Colitis: A Randomized Double-Blind Placebo-Controlled Study Stephan Miehlke, Ahmed Madisch, Diana Karimi et al. · Gastroenterology Open access	18 Mar 2009	178
12	Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial Walter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch et al. · Gut Open access	13 May 2010	175
13	Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis Wolfgang Hempfling, F Grünhage, Karin Dilger et al. · Hepatology	26 Jun 2003	166
14	Low-dose budesonide treatment for prevention of postoperative recurrence of Crohnʼs disease Klaus Ewe, Thomas Böttger, Heinz Johannes Buhr et al. · European Journal of Gastroenterology & Hepatology	Mar 1999	155
15	Budesonide versus Prednisone with Azathioprine for the Treatment of Autoimmune Hepatitis in Children and Adolescents Marek Woynarowski, Antal Németh, Yaacov Baruch et al. · The Journal of Pediatrics	28 Jun 2013	125
16	Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis Stephan Miehlke, Ahmed Madisch, Limas Kupčinskas et al. · Gastroenterology Open access	15 Jan 2014	120
17	Ursodeoxycholic acid — adverse effects and drug interactions Wolfgang Hempfling, K. Dilger, Ulrich H. Beuers · Alimentary Pharmacology & Therapeutics Open access	Nov 2003	119
18	A dose finding study with 0.1%, 0.2%, and 0.4% glyceryl trinitrate ointment in patients with chronic anal fissures J H Scholefield, J U Bock, B Marla et al. · Gut Open access	10 Jan 2003	116
19	Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health Karin Dilger, Simon D. Hohenester, Ursula Winkler–Budenhofer et al. · Journal of Hepatology	10 Mar 2012	116
20	The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine Wolfgang Kruis, Simon Bar–Meir, János Fehér et al. · Clinical Gastroenterology and Hepatology	2003	115
21	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA Gideon Morris Hirschfield, Ulrich H. Beuers, Limas Kupčinskas et al. · Journal of Hepatology Open access	17 Sep 2020	109
22	Trichuris suis and Trichuris trichiura are different nematode species Cristina Cutillas, Rocío Callejón, M. de Rojas et al. · Acta Tropica	24 May 2009	109
23	Budesonide in previously untreated autoimmune hepatitis Johannes Wiegand, Andreas Schüler, Stephan Kanzler et al. · Liver International	14 Jul 2005	104
24	Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study Wolfgang Kruis, Eberhard Meier, Martin M. Schumacher et al. · Alimentary Pharmacology & Therapeutics Open access	17 Feb 2013	100
25	Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis V. GROSS, Simon Bar–Meir, Alexandra Lavy et al. · Alimentary Pharmacology & Therapeutics Open access	22 Dec 2005	95
26	Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein Karin Dilger, Matthias Georg Schwab, Martin F. Fromm · Inflammatory Bowel Diseases Open access	19 Aug 2004	92
27	Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease Andreas Tromm et al. · Gastroenterology Open access	10 Nov 2010	90
28	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial Stefan Traussnigg et al. · The Lancet. Gastroenterology & hepatology	22 Jul 2019	87
29	Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial Andreas Münch et al. · Gut Open access	25 Nov 2014	86
30	Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis Wolfgang Kruis, Laimas Virginijus Jonaitis, Juris Pokrotnieks et al. · Alimentary Pharmacology & Therapeutics	8 Dec 2010	80
31	GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer Michael P. Flentje, Rudolf Maria Huber, Walburga Engel-Riedel et al. · Strahlentherapie und Onkologie	25 Jan 2016	77
32	Peripheral blood eosinophils and other non‐invasive biomarkers can monitor treatment response in eosinophilic oesophagitis Christoph Schlag, Stephan Miehlke, Alexander F. Heiseke et al. · Alimentary Pharmacology & Therapeutics	27 Aug 2015	76
33	6‐Thioguanine — efficacy and safety in chronic active Crohn's disease Klaus Robert Herrlinger, Wolfgang Kreisel, Matthias Georg Schwab et al. · Alimentary Pharmacology & Therapeutics	Feb 2003	75
34	Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis Stephan Miehlke et al. · Gastroenterology Open access	7 Sep 2018	71
35	Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers Martin Brunner, Roland Greinwald, Kurt Kletter et al. · Alimentary Pharmacology & Therapeutics Open access	May 2003	70
36	Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC Andreas Geier · World Journal of Gastroenterology Open access	2003	69
37	A Randomised, Double-blind, Placebo-controlled Trial ofTrichuris suisova in Active Crohn’s disease Jürgen Schölmerich, Klaus Fellermann, Frank Seibold et al. · Journal of Crohn s and Colitis Open access	5 Oct 2016	67
38	Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis Tilo Andus, Andreas Kocjan, Moritz Müser et al. · Inflammatory Bowel Diseases	22 Mar 2010	66
39	3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial Volker Groß, Ivan Bunganič, Elena A. Belousova et al. · Journal of Crohn s and Colitis Open access	15 Dec 2010	62
40	Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double‐blind, randomized, placebo‐controlled study Pokrotnieks, Pokrotnieks, Marlicz et al. · Alimentary Pharmacology & Therapeutics Open access	Sep 2000	62
41	Characterization of Eosinophilic Esophagitis From the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN Salvatore Oliva et al. · Journal of Pediatric Gastroenterology and Nutrition	16 Jun 2022	56
42	Ursodeoxycholic Acid Treatment in Preterm Infants: A Pilot Study for the Prevention of Cholestasis Associated With Total Parenteral Nutrition Sertaç Arslanoğlu, Guido Eugenio Moro, Horst‐Dietmar Tauschel et al. · Journal of Pediatric Gastroenterology and Nutrition	Feb 2008	52
43	Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease Valeriia Dotsenko et al. · Nature Immunology Open access	24 Jun 2024	50
44	Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD Hartmut Bertz, Matthias Afting, Wolfgang Kreisel et al. · Bone Marrow Transplantation	Dec 1999	50
45	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study Wolfgang Kreisel, Peter Deibert, Limas Kupčinskas et al. · Digestive and Liver Disease	17 Nov 2014	50
46	Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis Peter G. Gibson, B Fixa, B. Pekárková et al. · Alimentary Pharmacology & Therapeutics	17 Mar 2006	49
47	Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer Meinolf Karthaus, Harald Balló, Wolgang Abenhardt et al. · Oncology	2005	49
48	Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial Axel U Dignass, Simeon G Stoynov, Andrey E. Dorofeyev et al. · Journal of Crohn s and Colitis Open access	15 Feb 2014	48
49	Predictors of premature delivery in patients with intrahepatic cholestasis of pregnancy Jūratė Kondrackienė, Ulrich H. Beuers, Rimantas Žalinkevičius et al. · World Journal of Gastroenterology Open access	2007	46
50	A double‐blind dose‐escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis Y Marakhouski, B Fixa, Jozef Holomáň et al. · Alimentary Pharmacology & Therapeutics Open access	2005	45

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.